FB-1006
- Generic Name
- FB-1006
Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
Phase 4
Recruiting
- Conditions
- Sporadic and Familial Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT05923905
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath